Anna Riccio

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus.

Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus.

Journal: Virus research

Published: January 12, 2026

Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles.

Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles.

Journal: Viruses

Published: March 06, 2025

4-Aza Cyclopentenone Prostaglandin Analogues: Synthesis and NF-κB Inhibitory Activities.

4-Aza Cyclopentenone Prostaglandin Analogues: Synthesis and NF-κB Inhibitory Activities.

Journal: ChemMedChem

Published: October 18, 2024

Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: Impact on virus-induced COX-2 expression.

Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: Impact on virus-induced COX-2 expression.

Journal: Journal of virus eradication

Published: June 07, 2024

Human coronaviruses activate and hijack the host transcription factor HSF1 to enhance viral replication.

Human coronaviruses activate and hijack the host transcription factor HSF1 to enhance viral replication.

Journal: Cellular and molecular life sciences : CMLS

Published: May 04, 2024

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein.

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein.

Journal: Frontiers in microbiology

Published: April 16, 2023

Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery.

Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: June 28, 2022

Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence.

Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence.

Journal: Cellular and molecular life sciences : CMLS

Published: January 05, 2022

Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy.

Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 29, 2021

The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.

The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.

Journal: Biochemical and biophysical research communications

Published: October 26, 2020

The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction.

The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction.

Journal: Cellular and molecular life sciences : CMLS

Published: December 30, 2019

The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.

The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.

Journal: Molecular cancer research : MCR

Published: March 08, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026